Ying-Chieh Lin1, Yu-Ching Chen1, Jorng-Tzong Horng1,2, Jui-Ming Chen1,3. 1. Department of Bioinformatics and Medical Engineering, Asia University, Taichung 41354, Taiwan. 2. Department of Computer Science and Information Engineering, National Central University, Chungli 32001, Taiwan. 3. Department of Endocrinology and Metabolism, Tungs' Taichung MetroHarbor Hospital, Taichung 43503, Taiwan.
Abstract
Background and Objectives: Fenofibrate, a PPAR-α agonist, has been demonstrated to reduce the progression of diabetic retinopathy (DR) and the need for laser treatment in a FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study. However, in the subgroup of patients without pre-existing DR, there was no significant difference in the progression of DR between the fenofibrate group and the placebo group. In this study, we aim to investigate whether fenofibrate can decrease the risk of incident DR in a population-based cohort study of type 2 diabetic patients in Taiwan. Materials and Methods: A total of 32,253 type 2 diabetic patients without previous retinopathy were retrieved from 892,419 patients in 2001-2002. They were then divided into two groups based on whether they were exposed to fenofibrate or not. The patients were followed until a diagnosis of diabetic retinopathy was made or until the year 2008. Results: With a follow-up period of 6.8 ± 1.5 years and 5.4 ± 2.6 years for 2500 fenofibrate users and 29,753 non-users, respectively, the Cox proportional hazard regression analysis revealed that the hazard ratio (HR) of new onset retinopathy was 0.57 (95% CI 0.57-0.62, p < 0.001). After adjusting for hypertension; the Charlson comorbidity index (CCI); and medications such as angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARB), anticoagulants, gemfibrozil, statins, and hypoglycemic agents, the adjusted HR was 0.75 (95% CI 0.68-0.82, p < 0.001). The need for laser treatment has an HR and adjusted HR of 0.59 (95% CI 0.49-0.71, p < 0.001) and 0.67 (95% CI 0.56-0.81, p < 0.001), respectively. Conclusion: Our study showed that the long-term and regular use of fenofibrate may decrease the risk of incident retinopathy and the need for laser treatment in type 2 diabetic patients. Since there are limitations associated with our study, further investigations are necessary to confirm such an association.
Background and Objectives:Fenofibrate, a PPAR-α agonist, has been demonstrated to reduce the progression of diabetic retinopathy (DR) and the need for laser treatment in a FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study. However, in the subgroup of patients without pre-existing DR, there was no significant difference in the progression of DR between the fenofibrate group and the placebo group. In this study, we aim to investigate whether fenofibrate can decrease the risk of incident DR in a population-based cohort study of type 2 diabeticpatients in Taiwan. Materials and Methods: A total of 32,253 type 2 diabeticpatients without previous retinopathy were retrieved from 892,419 patients in 2001-2002. They were then divided into two groups based on whether they were exposed to fenofibrate or not. The patients were followed until a diagnosis of diabetic retinopathy was made or until the year 2008. Results: With a follow-up period of 6.8 ± 1.5 years and 5.4 ± 2.6 years for 2500 fenofibrate users and 29,753 non-users, respectively, the Cox proportional hazard regression analysis revealed that the hazard ratio (HR) of new onset retinopathy was 0.57 (95% CI 0.57-0.62, p < 0.001). After adjusting for hypertension; the Charlson comorbidity index (CCI); and medications such as angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARB), anticoagulants, gemfibrozil, statins, and hypoglycemic agents, the adjusted HR was 0.75 (95% CI 0.68-0.82, p < 0.001). The need for laser treatment has an HR and adjusted HR of 0.59 (95% CI 0.49-0.71, p < 0.001) and 0.67 (95% CI 0.56-0.81, p < 0.001), respectively. Conclusion: Our study showed that the long-term and regular use of fenofibrate may decrease the risk of incident retinopathy and the need for laser treatment in type 2 diabeticpatients. Since there are limitations associated with our study, further investigations are necessary to confirm such an association.
Entities:
Keywords:
diabetic retinopathy; fenofibrate; type 2 diabetic
Authors: Nish Chaturvedi; Massimo Porta; Ronald Klein; Trevor Orchard; John Fuller; Hans Henrik Parving; Rudy Bilous; Anne Katrin Sjølie Journal: Lancet Date: 2008-09-25 Impact factor: 79.321
Authors: J W J Beulens; A Patel; J R Vingerling; J K Cruickshank; A D Hughes; A Stanton; J Lu; S A McG Thom; D E Grobbee; R P Stolk Journal: Diabetologia Date: 2009-07-25 Impact factor: 10.122
Authors: Feng Hua Wang; Yuan Bo Liang; Feng Zhang; Jie Jin Wang; Wen Bin Wei; Qiu Shan Tao; Lan Ping Sun; David S Friedman; Ning Li Wang; Tien Yin Wong Journal: Ophthalmology Date: 2009-01-24 Impact factor: 12.079
Authors: Joanne W Y Yau; Sophie L Rogers; Ryo Kawasaki; Ecosse L Lamoureux; Jonathan W Kowalski; Toke Bek; Shih-Jen Chen; Jacqueline M Dekker; Astrid Fletcher; Jakob Grauslund; Steven Haffner; Richard F Hamman; M Kamran Ikram; Takamasa Kayama; Barbara E K Klein; Ronald Klein; Sannapaneni Krishnaiah; Korapat Mayurasakorn; Joseph P O'Hare; Trevor J Orchard; Massimo Porta; Mohan Rema; Monique S Roy; Tarun Sharma; Jonathan Shaw; Hugh Taylor; James M Tielsch; Rohit Varma; Jie Jin Wang; Ningli Wang; Sheila West; Liang Xu; Miho Yasuda; Xinzhi Zhang; Paul Mitchell; Tien Y Wong Journal: Diabetes Care Date: 2012-02-01 Impact factor: 19.112